Changing the receipt dates
Find Funding Opportunities
NIH Extramural Response to Natural Disasters and Other Emergencies
In emergency situations, the NIH’s immediate concern is for the health and safety of people and animals in the programs we oversee. Visit the NIH Extramural Response to Natural Disasters and Other Emergencies web page for biomedical research community resources, including NIH Guide Notices and other information of particular relevance to investigators and their institutions, links to web pages listing NIH’s response to certain major events (past and present); and links to similar web sites from other Federal agencies.
COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements
All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.
Learn more about award types and program directors and managers.
NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!
For more focused results add quotes to indicate parameters. Example format: "search term".
Notice of Change to Receipt Dates for RFA-NS-22-069: "HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional)"
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-23-099
Monday, December 4, 2023
Notice Type: NOT
Notice of Change to Key Dates for RFA-NS-24-023: HEAL INITIATIVE: Development and validation of remote or patient wearable device derived objective biosignatures or functional assessments to monitor pain for use as endpoints in clinical trials (UG3/UH3)
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-24-029
Monday, December 4, 2023
Notice Type: NOT
Adding a receipt date.
Notice of Change: Extension of PAR-22-030 "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)" by one Council Round
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-24-020
Thursday, November 30, 2023
Notice Type: NOT
The purpose of this notice is to inform applicants of an extension to PAR-22-030 "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)". The NOFO will be extended by one additional council round.
Notice of Change: Extension of PAR-22-028 "Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)" by one Council Round
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-24-035
Thursday, November 30, 2023
Notice Type: NOT
The purpose of this notice is to inform applicants of an extension to PAR-22-028 "Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)". The NOFO will be extended by one additional council round.
Notice of Change: Extension of PAR-21-224 "NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)"
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-24-037
Thursday, November 30, 2023
Notice Type: NOT
The purpose of this notice is to inform applicants of an extension to PAR-21-224 "NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)". This notice of funding opportunity (NOFO) is being extended by one additional council round.
Technical Assistance Webinars for RFA-NS-24-029 Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)"
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-24-036
Monday, November 27, 2023
Notice Type: NOT
The purpose of this notice is to inform applicants of an informational webinar for RFA-NS-24-029 Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)".
Notice of Change to IC-specific Information for the NINDS for PAR-22-105 and PAR-22-109 Dissemination and Implementation Research in Health NOFOs
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-24-032
Wednesday, November 22, 2023
Notice Type: NOT
The purpose of this notice is to inform applications of NINDS' IC-specific information for PAR-22-105 Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) and PAR-22-109 Dissemination and Implementation Research in Health (R21 Clinical Trial Optional).
Notice of Change to IC-specific Information for the NINDS for PAR-22-106 Dissemination and Implementation Research in Health NOFO
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-24-034
Monday, November 20, 2023
Notice Type: NOT
The purpose of this notice is to inform applications of NINDS' IC-specific information for PAR-22-106 Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed).
Notice of termination of the NINDS Postdoctoral Mentored Career Development Award K01 (PAR-23-143 and PAR-23-142)
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-24-031
Wednesday, November 15, 2023
Notice Type: NOT
This notice is provided to inform the public that the final receipt date for PAR-23-142 NINDS Postdoctoral Mentored Career Development Award (K01 Clinical Trial Required) and PAR-23-143 NINDS Postdoctoral Mentored Career Development Award (K01 No Independent Clinical Trial Allowed) will be February 12, 2024. NINDS will not reissue these notices of funding opportunity (NOFOs). NINDS will continue to utilize the F32 and K99/R00 mechanisms specifically intended to support postdoctoral fellows.
Notice of Correction to Expiration Date for PAR-24-063 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)"
Expiration Date: Monday, January 1, 2029
NOFO Number: NOT-NS-24-030
Monday, November 13, 2023
Notice Type: NOT
The purpose of this notice is to correct the expiration date for PAR-24-063 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)".